Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

[2] Measures of effectiveness include pregnancy rate per treatment cycle, cumulative clinical pregnancy rate (CCPR) and cumulative live-birth rate (CLBR), while rates of HIV seroconversion and ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

This includes employment, consultancies, honoraria, stock ownership or options ... are screened to ensure minimization of HIV transmission during treatment. Male and female seropositive partners ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...